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Resumo 
 
Os genes HOX codificam fatores de transcrição cruciais para o desenvolvimento 
embrionário, que afetam a proliferação celular, diferenciação, migração e apoptose. No 
entanto alguns destes genes são também expressos no tecido adulto e frequentemente 
desregulados em processos cancerígenos, como é o caso do cancro de mama, a 
principal causa de morte nas mulheres, devido a doença oncológica. Resultados 
preliminares do nosso laboratório, demonstraram que o gene HOXB7 é sobre-expresso 
em linhas celulares de cancro da mama representativas dos distintos subtipos molecular 
usados na clínica. No entanto estes resultados não foram replicáveis num grupo de 
pacientes com cancro de mama do IPO-Porto. 
O principal objetivo desta dissertação foi aprofundar a caracterização da expressão dos 
genes HOXB7 e HOXB9 nestes pacientes. Com esta finalidade, realizaram-se análises 
de qPCR para avaliar os níveis de mRNA do HOXB9 em biopsias de tecido normal e 
cancerígeno. De seguida, foi otimizado o protocolo para analisar a expressão proteica 
do HOXB9 por western blot. O nível proteico do HOXB7 e HOXB9 em pacientes, foi 
explorado também por imunohistoquímica, o que envolveu igualmente otimização de 
protocolos.  
A analise quantitativa dos níveis de mRNA e de proteína revelaram níveis de expressão 
mais altos nos tecidos normais do que nos tecidos cancerígenos, o que contraria os 
resultados preliminares realizados em linhas celulares no nosso laboratório e também 
outros estudos publicados.  
Este trabalho permitiu a otimização de protocolos visando a caracterização da 
expressão do HOXB7 e HOXB9 em cancros de mama, tendo em conta distintos subtipos 
moleculares, e enalteceu a necessidade de aumentar o número de casos estudados e 
de incorporar controlos visando uma menor heterogeneidade genética. Adicionalmente, 
os dados obtidos por imunohistoquímica permitiram uma caracterização das células e 
das estruturas mamárias que demonstram aberrante expressão destes genes durante 
os desenvolvimentos do cancro da mama, tendo em conta os diferentes subtipos 
moleculares, o que é relevante para a consolidação do estudo da sua função nestes 
contextos oncológicos.  
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Abstract 
 
HOX genes encode transcription factors crucial for embryonic development that affect 
cell proliferation, differentiation, migration, and apoptosis. However, some of these 
genes are also expressed in adult tissue and are often deregulated in cancerous 
processes, such as breast cancer, the leading cause of death in women due to cancer. 
Preliminary results from our laboratory demonstrated that the HOXB7 gene is 
overexpressed in breast cancer cell lines representing the distinct molecular subtypes 
used in the clinic. However, these results were not replicable in a group of IPO-Porto 
breast cancer patients. 
The main objective of this dissertation was to further characterize the expression of 
HOXB7 and also HOXB9 in these patients. To this end, qPCR analyzes were performed 
to evaluate HOXB9 mRNA levels in normal and carcinogenic tissues. Then, the protocol 
to analyze HOXB9 protein levels by western blot was optimized. The protein level of 
HOXB7 and HOXB9 in patients was also explored by immunohistochemistry, which also 
involved protocol optimization. 
Quantitative analysis of mRNA and protein levels revealed higher expression levels in 
normal tissues than in cancerous tissues, which contradicts preliminary results 
performed on cell lines in our laboratory and also other published studies. 
This work allowed the optimization of protocols aiming to characterize HOXB7 and 
HOXB9 expression in breast cancers, taking into account different molecular subtypes, 
and emphasized the need to increase the number of cases studied and to incorporate 
controls aiming at less genetic heterogeneity. Additionally, data obtained by 
immunohistochemistry will allow characterization of breast cells and structures showing 
aberrant expression of these genes during the development of breast cancer, 
considering the distinct molecular subtypes, which is relevant to consolidate study 
addressing their function in these oncological contexts. 
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1. Introduction  
 2 
1.1 Breast Cancer 
 
1.1.1 Epidemiology  
 
Oncological diseases are extremely common in Europe, affecting 1 in 4 people throughout 
their lifetime. In addition, these diseases figure among the most common causes of death 
in Europe and, as for other main causes of death, affect most significantly the men 
population (Fig.1) [1]. The only exception, in which a main cause of death affects more 
women than men, is breast cancer (BrCa). After lung cancer, which has the highest number 
of new cases and deaths per year, BrCa is the second most common cancer type, affecting 
women in the world [2, 3]. In 2018, 2 million new cases of this oncological disease have 
been identified worldwide and it was also the most incident type of cancer among women, 
and also the deadliest [4, 5]. However, men also develop BrCa but in a much lower 
percentage, which represents about 1% of the diagnosed cases [6]. 
 
Figure 1 - Main causes of death in Europe (Last Eurostat data from 2015, EU), standardized rates 
per 100 000 inhabitants. Note higher mortality for the women population, in comparison with the men 
population, detected only for malignant neoplasm of breast (arrow). 
 
Within the first 25 countries with the highest rate of BrCa, 19 are from Europe and 24 are 
from countries classified as having “upper middle” to “high” per capita gross national income 
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(Tab.1). This has been related with risk factors more prevalent in these countries such as 
aging of the population, low parity, increasing age of the first pregnancy, use of birth control 
and post-menopausal medication, obesity, physical inactivity, among others [7]. In countries 
with high income, BrCa incidence and mortality are expected to decrease, due to advances 
in early diagnosis and therapy, while in underdeveloped countries the opposite tendency is 
expected [8]. Recent studies suggest that the increasing incidence of BrCa in Northern and 
Eastern Europe is associated to mammography screening and reduction of post-
menopausal hormonal replacement therapy [2]. However, these countries have available 
the best early detection programs, neo-adjuvant therapies and health care in general, which 
is contributing to decrease BrCa  mortality. In contrast, in underdeveloped countries the 
number of BrCa cases is expected to increase, associated to risk factors such as obesity, 
physical inactivity, late first-pregnancy or smoking but also due to lack of routine screenings 
and poor health care [2]. In these countries, the number of new BrCa cases is expected to 
ascends to 2.4 million per year worldwide in 2030 [9].  
Table 1 - Top 25 countries with highest rates of breast cancer worldwide. Three first columns show 
data from Continuous Update Project for 2018 [5] and last column indicates the economic status of 
each country/region, according to the report on World Economic Situation and prospect in 2014 
(United Nations) [10]. 
 
 
 
In Portugal, BrCa incidence rates have been rising for years (Fig.2) [11, 12]. Also in 
Portugal, this oncological disease is the most common cancer type and the principal cause 
of cancer mortality in women, accounting for 30% of all cancer cases and 16% of all cancer 
 4 
deaths in 2012 [7]. Two recent studies addressed the incidence in distinct country regions 
and found a higher number of cases for most age groups in Lisbon area [11, 12]. In general, 
the South presents the highest age-standardized rate (155.8/100 000 inhabitants), while the 
North presents the quickest rate of increase (3.6%/year). Therefore, these studies suggest 
that the Northern region could be number one among all regions in a few years. For now, 
younger women from the North have lower risk to develop BrCa in comparison to women 
with the same age gap from South and Centre. However, this risk is reversed in older 
women. The authors of these studies suggest that differences found in distinct regions of 
the country might be due to a combination of different diagnostic practices and/or exposure 
to different risk factors. The heterogeneity of the disease in younger and older women may 
also explain partially the differences in age-specific rates [12]. The number of diagnosed 
cases in Azores and Madeira was much lower than in the continental region, representing 
only 4,2% of the cases occurring in the time period from 1998 through 2011 [11].  
  
Figure 2  -BrCa incidence in Portugal 1998–2011 (overall and by region) [11]. Age-standardized rates 
from women aged 30-84 years and in specific age-groups (30–44, 45–69, 70–84 years). 
 
1.1.2 Risk Factors 
 
The identification of risk factors associated to the development of BrCa is a critical step for 
the prevention of this disease. There are 5 major categories of risk factors that have been 
associated to BrCa 1) aging, 2) family history, 3) genetics, 4) estrogen levels and 5) life 
habits.  
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1) Aging: It is the major risk factor for BrCa, which has an increasing incidence 
throughout a woman´s lifetime [13]. For example, 2 in 3 women with an Invasive 
BrCa are over 55 years old and post-menopausal.  This is explained by 
accumulation of genetic damage (mutations) throughout life that eventually 
promotes oncological processes. However, it is also true that BrCa that occurs in 
younger ages, prior to 40 years old, are more difficult to treat, have higher risk of 
relapse and cause more death [14]. The first screening age, ideal according to 
several studies, is between 40-45 years, in order to detect BrCa with worse 
prognosis [14]. However, when women have family history of BrCa, they are advised 
to start the screening much earlier, at the age of 25. Thus, the genetic background 
alters the age of BrCa risk. An intriguing example was found in African-American 
women, which seems more prone to develop aggressive BrCa types before the age 
of 40, contrarily to Caucasian-American women [13].  
 
2) Family history: It is strongly relevant for the risk to develop BrCa. As above 
mentioned, certain types of BrCa (5% to 10%) are related with hereditary genetic 
background and those are the ones affecting younger women and responsible for 
higher mortality rate. Thus, the risk for BrCa directly relates with the number of first-
degree relatives with this disease. Moreover, even in older women the genetic 
background is relevant for the outcome of the disease. Thus, post-menopausal 
women with familiar history of BrCa have much higher risk to develop this disease. 
In certain cases, a strong family history of BrCa is linked to mutated genes, such as 
BRCA1, BRCA2 gene or CHEK2 gene, which play a central role in the development 
of different types of BrCa [15]. 
 
3) Genetics: DNA damage causes abnormal cell growth and function and is 
strongly associated to oncogenesis. It can be inherited or appear de novo over the 
course of life, resulting from natural aging or exposure to chemicals in the 
environment. Most inherited cases of BrCa are associated to mutations in BRCA1 
and BRCA2 genes, involved in cell damage repair [16]. Women with BRCA1 or 
BRCA2 mutations (or both) have up to a 72% risk of being diagnosed with BrCa, 
which occurs particularly in younger women. They are tumour suppressors crucial 
for the repair of double-strand DNA breaks. BRCA1 is also necessary for cell 
replication and DNA synthesis, but due to epigenetic inactivation or mutations, 
increases BrCa risk [17-19]. Single nucleotide polymorphisms (SNPs) seem to 
increase BrCa risk in women with or without BRCA1 mutation. Several other gene 
mutations have been associated to high risk of BrCa: ATM (DNA repair); BARD1 
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(DNA repair); BRIP1 (DNA repair); CDH1 (cell adhesion); CHEK2 (cell growth 
regulation); MRE11A (DNA repair); MSH6 (DNA repair); NBN (DNA repair); PALB2 
(DNA repair); PMS2 (DNA repair); PTEN (cell growth regulation); RAD50 (DNA 
repair); RAD51C (DNA repair); STK11 (cell growth regulation); TP53 (cell growth 
regulation); HER2 (epidermal growth factor receptor, which activates cell 
proliferation, survival and adhesion) [20-24].   
 
4) Estrogen levels: Early menarche and late menopause increase BrCa risk, 
given the increased exposition to estrogens [25]. The breast cells from women that 
did not have a full-term pregnancy remain very active and responsive to estrogen. 
Thus, these women have a higher BrCa risk [25, 26]. Due to an increased exposure 
to estrogen, women who have their first child after age of 30 also have higher BrCa 
risk compared to women who gave birth before that. Pregnancy also reduces the 
total number of lifetime menstrual cycles, which may explain its protective effect 
against BrCa. Lactation also decreases BrCa risk, especially if it lasts longer than 1 
year. Women who started menstruating younger than age 12 have higher BrCa risk 
later in life, as well as women who go through menopause older than 55. The earlier 
breasts form, the sooner they interact with internal or external hormones and with 
chemicals in hormone disruptor products, which increases BrCa risk. In addition, the 
hormonal replacement therapy (HRT) used by post-menopausal women have been 
strongly associated to BrCa diagnosis, increasing the risk up to 75% [27].  
 
5) Life habits: Diets rich in carbohydrates and fat, combined with lack of 
exercise, frequently conduct to overweight and obesity, which increases the risk of 
BrCa, especially after menopause. In addition, overweight and obesity also increase 
the risk of recurrence after treatment. This relation between body weight and BrCa 
risk is due to the capacity of the adipocytes to produce estrogen, which may trigger 
BrCa develop and grow. The higher is the exposition to extra estrogen over time, 
the higher is the risk to develop BrCa. Several studies also show an association 
between exercising regularly (4 to 7 hours/week) to a lower BrCa risk. Regular 
exercise seems to lower the levels of insulin growth factor in the blood, hormone 
that can affect BrCa development. Moreover, people that exercise regularly tends 
to maintain a healthy weight, therefore, having less body fat than inactive people. 
Regarding diet, it is also known that women with an abundant processed meat or 
fast food intake have higher BrCa risk than women with a diet rich in fruits and 
vegetables [28]. Alcohol consumption is associated with BrCa risk in women, by 
increasing the levels of estrogen and other hormones associated with hormone-
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receptor-positive BrCa or by damaging the DNA. The consumption of three alcoholic 
drinks per week seems to be enough to increase the risk of BrCa 15% and the risk 
goes up another 10% for each additional drink women regularly have each day. 
There are also some evidences that alcohol consumption, even a few beverages 
per week, increase the risk of relapse after BrCa treatment. Importantly, girls from 9 
to 15 years old that consume 3 to 5 drinks per week have 3 times more probability 
to develop benign breast lumps, which later in life can become carcinogenic. In 
addition, smoking is linked to a higher risk of BrCa in younger, premenopausal 
women and very heavy second-hand smoke exposure increases BrCa risk in 
postmenopausal women. Moreover, Catsburg and colleagues, found a positive 
association between duration and intensity of cigarette smoking, as well as being a 
smoker prior to first pregnancy, with the risk to develop BrCa [29].  
 
1.1.3 Man Breast Cancer 
 
Male BrCa is rare and it can affect 1 in 100,000 men, accounting for 1% of all BrCa cases 
diagnosed [30]. It has some similarities with females BrCa, however, upon its discovery, it 
tends to present a more advanced stage, and consequently a worse prognosis [31]. In all 
male BrCa cases, the most common type of invasive carcinoma is the ductal, being the in 
situ and invasive lobular carcinomas the most rare cases in males [32]. Incidence of male 
BrCa cancers increases with age (>60) and is influenced by the genetic background, 
particularly associated to the BRCA1 and BRCA2 mutations [6]. About of 20% male BrCa 
cases have a first-degree family member with BrCa [32, 33]. The Klinefelter syndrome, 
gynecomastia, prostate, testicular or liver diseases, obesity, or alcohol consume, can have 
an impact on the incidence of man BrCa [34]. In addition, occupational exposures to 
radiation or polycyclic aromatic hydrocarbons could have an implication on the appearance 
of these cancers in males [35]. Decrease in mortality in male breast cancer is particularly 
associated to adjuvant systemic treatments, since there is no screening implemented for 
men [36]. Due to the lack of mammary tissue in males, skin and chest wall involvement is 
not rare and mastectomy is the standard surgical treatment [32].  
 
1.1.4 Screening 
 
BrCa screening is done by evaluating the breast before any signs or symptoms of the 
disease and is a practice implemented in several countries [37]. These trials have proven 
that screen-detected, non-palpable, preclinical tumours of ≤ 15 mm have a better prognosis. 
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Therefore, BrCa screening is helping to diminish the death associated to this disease. 
However, incidence of breast cancer is still increasing, in part due to a more efficient 
detection using periodical screening, along with an increase of the risk factors [38]. 
Currently, there are four reliable methods for BrCa detection: mammography, breast 
magnetic resonance (MRI), clinical breast exam and breast self-awareness [9]. The most 
valid and reliable method is mammography, since it can detect BrCa at an early stage, when 
treatment is more likely to have a positive outcome [39]. This is a multidisciplinary method 
and accuracy rate can be from 85% to 90%, which will lead to a reduction in mortality rate 
from 30% to 50% [9, 40]. However, risk of over-diagnosing or false-positive screening has 
to be taken into account of this method [37]. In families with BRCA mutation, screening is 
performed annually with magnetic resonance imaging and mammography combined, to 
detect the cancer at less invasive stage [37]. Clinical   exam is also important for early stage 
detection and surveillance, spatially in women that have a greater risk for BrCa. In this group 
are included women with radiographically dense breasts, breast implants, women who have 
been submitted to radiotherapy or patients without access to an optimal health care [9]. This 
examination consists in a manual palpation of the breasts and local regional lymph nodes 
[41]. In countries with low income and underdeveloped health services, breast self-exam is 
an alternative approach that should not be, however, neglected even when there are other 
resources [9]. 
In order to positively confirm BrCa, a sample of the primary tumour and cytology/histology 
of axillary nodes, if involvement is suspected, needs to be analyzed by a pathologist [37]. 
The sample should be taken with a core needle biopsy, and must be retracted before any 
treatment for pathological diagnosis, who should be done according to the World Health 
Organization classification and the tumour-node-metastasis staging system [37]. The exam 
should analyze histologic type and grade, and determination of estrogen receptor (ER), 
progesterone receptor (PgR) and HER2 receptor status by IHC or FISH/CISH assay [41]. 
 
1.1.5 Breast anatomy 
 
The breast, or mammary gland, is a structure able to produce milk in females. It is composed 
mainly by adipose tissue and extends from the collarbone down to the underarm and across 
to the middle of the ribcage (Fig.3). It can present different anatomies and physiologies, 
depending on age, hormonal status, genetic background and daily life habits [42] and, as 
glandular structures, they are very perceptive to hormonal changes in the body [43]. They 
have lobes, which are divided into smaller lobules connected via milk ducts [43]. The 
adipose tissue of the breast is supplied by a network of nerves, blood vessels, lymph 
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vessels, lymph nodes, and is also composed by fibrous connective tissue and ligaments 
[43].  
 
Figure 3 - Breast anatomy. All mammals have mammary glands that produce breast milk to feed 
their offspring [44]. 
 
1.1.6 Histopathological types  
 
BrCa is a highly heterogeneous pathology that has different clinical outcomes and 
responsiveness to treatments [45, 46]. In fact, several lines of evidence suggest that BrCa 
is, in fact, a collection of different diseases with distinct risk factors, clinical presentation, 
pathological characteristics, response to therapy and outcomes, which originate in the same 
anatomical structure (the terminal duct-lobular unit) [47]. Most BrCa are adenocarcinomas 
(95%) and their phenotypic range can be correlated with diversity in gene expression 
patterns [46]. Bearing in mind the cell morphology, growth and architecture patterns, there 
are more than 21 histological subtypes described [48]. However, BrCa can be divided into 
in situ and invasive carcinomas, which are classified as ductal or lobular according to the 
origin site [49, 50].  
1) Ductal carcinoma in situ (DCIS) is non-invasive potentially malignant intraductal 
proliferation of epithelial cells, characterized by cellular or nuclear atypia, that can 
evolve to invasive carcinoma [49]. Classification of DCIS depends on the degree of 
nuclear atypia, intraluminal necrosis, miotic activity and calcification, then it can be 
divided into three types, Low-Grade, Intermediate-Grade and High-grade, which are 
correlated to the risk of becoming invasive [49]. Historically, DCIS has been 
classified into five architectural subtypes: comedo, solid, cibriform, papillary and 
micropapillary. DCIS is consistently positive for E-cadherin and β-catenin. 
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2) Lobular carcinoma in situ (LCIS) is characterized by intra-lobular proliferation of 
small, and loosely cohesive cells, originated in the terminal duct lobular unit (TDLU). 
It constitutes a risk factor but a nonobligatory precursor for subsequent development 
of invasive carcinoma [49]. There are two immunohistochemical markers to 
distinguish LCIS, the lack of E-cadherin and β-catenin expressions and the positivity 
for high molecular weight (HMW) keratin [51].  
 
3) Invasive ductal carcinoma (IDC) is a malignant ductal proliferation along with stromal 
invasion in the presence or absence of DCIS and can be classified according to cell 
type, number, type and location of secretion, architectural features and 
immunohistochemical profile [49]. It is the most frequent invasive breast cancer and 
accounts for 55% of breast cancer incidence upon diagnosis.  
 
4) Invasive lobular carcinoma (ILC) is a malignant abnormal proliferation of neoplastic 
cells in the lobules, which invaded the stroma. ILC represents 5-15% of all breast 
cancer cases, and its incidence appears to be increasing, affecting postmenopausal 
women, and it could be related to hormone replacement treatment. ILC has 5 distinct 
histological groups, classic type, pleomorphic, histiocytoid, signet ring and 
tubolobular [49]. 
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Figure 4 - BrCa pathogenesis and histologic versus molecular subtypes, by Eric Wong and Joana 
Rebelo. 
 
1.1.7 Molecular subtypes 
  
Human BrCa heterogeneity correlates with different gene expression patterns [52], which 
can be used as a prognostic marker [53]. Using hierarchical clustering, Perou and 
colleagues realized that part of the BrCa produce estrogen receptor (ER+) and the 
remaining one do not produce this hormone receptor (Fig.4,5) [52]. The ER+ tumours fall 
into luminal subtypes (A and B), given that the luminal cells have the most enriched levels 
of ER. The ER- tumours (low to absent) fall into Basal, HER2-enriched, Normal Breast-Like 
subtypes and Triple Negative [53, 54].  
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Figure 5 - Schematic illustrations of the five major clusters that represent the molecular subtypes of 
BrCa based on Perou and colleagues work carried out a cDNA microarray analysis of 38 invasive 
BrCa, 1 ductal carcinoma in situ, 1 fibroadenoma and 3 normal breast samples, and a number of 
biological replicates of tumours from the same patients [52]. Hierarchical clustering led to identify 
four subtypes: luminal, normal breast-like, human epidermal growth factor receptor 2 (HER2), and 
basal like. Later, it was shown that similar molecular subtypes can be identified in multiple cohorts 
and that luminal cancers can be subclassified into luminal A and B [53]. 
 
Thus, there are five molecular subtypes of BrCa according to their gene expression profiles 
belonging to five distinct groups:  
1) Luminal tumours are the most common subtype of BrCa cases, and they can be 
divided into two subtypes, Luminal A and B, being the luminal A the most common. 
These subtypes express hormone receptors for estrogen (ER) and progesterone 
(PR). However, while Luminal A does not express the human epidermal growth 
factor receptor 2 (HER2) and have low levels of Ki-67 protein, which is involved in 
tumour growth regulation, the luminal B subtype may express or not HER2, always 
have high levels of the protein Ki-67 [50, 54]. Luminal B tumours have a higher 
expression of genes involved in cell proliferation when compared with luminal A 
subtypes [55]. In general, luminal tumours have a good prognosis, but luminal A 
subtype have a significant better prognosis than luminal B subtype, being a low-
grade subtype, while luminal B usually is a higher-grade, having a lower survival 
rate [50, 54].  
2) The HER2+ enriched subtype, are not only overexpressing this gene but are also 
amplifying other genes in the HER2 amplicon, 40 to 80% of tumours from this 
molecular subtype have a mutation related to p53 gene, subsequently being 
associated with a poor prognosis [50, 54, 56]. This group also has a low expression 
of basal-related genes such as keratin 5 [55]. 
3) Basal tumours have an increased expression of basal markers such as keratins 5, 
6, 14 and 17, and EGFR. This molecular subtype is also known to have increased 
expression of genes related with proliferation and to higher probability to present 
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low BRCA1 expression, and higher frequency of p53 mutation, which controls 
proliferation and maintains the integrity and stability of the genome, this gene is 
actually mutated in approximately in 80% of the cases [54, 57-59]. Most cases of 
basal tumours are triple negative breast cancer cases (TNBC), which account for 
60-90%, of these tumours. TNBCs do not express ER and PR, and HER2 gene is 
not amplified or overexpressed [54, 60]. Overall, TNBC presents an aggressive 
phenotype, being histologically classified as high-grade, invasive, ductal carcinomas 
of no special type with basal-like features, thus it would not express biomarkers such 
as ER, PR and HER2, but would express cytokeratins, EGFR, vimentin and p-
cadherin, which are characteristic of high-grade invasive breast carcinomas [60, 61]. 
4) Recent studies have defined a new molecular subtype of BrCa, claudin-low, which 
is typically triple negative. This subtype is characterized by downregulation of tight 
junction proteins, such as E-cadherin, and by overexpression of genes associated 
with epithelial-mesenchymal transition and BrCa cell phenotype [50, 59, 62].  
5) Another subtype of BrCa is the normal-like subtype, which is a controversial group 
since some authors think that this subtype represents normal cell contamination on 
samples rather than a real subtype, also this group expresses genes associated 
with adipose tissue and other stromal cell types [50]. This subtype accounts for 7,8% 
of all breast cancer cases, and its gene expression is characterized by a high 
expression of genes of basal epithelial cells and adipose cells [52, 54].  
 
1.1.8 Biological Markers  
 
After BrCa diagnosis, there is the need to determine patient prognosis and identification of 
the most appropriate adjuvant systemic treatment. For a more accurate prognosis, some 
characteristics can be reviewed such as clinicopathological prognostic factors and 
predictive biological markers. Clinicopathological characteristics include lymph nodes with 
metastasis, tumour size and tumour grade. Although there are several new molecular tests, 
these factors are still very important for aiding therapy in newly diagnosed cases [63]. 
However, these markers are insufficient for proper patient treatment, especially in a time 
where personalized care is becoming a fundamental aim in biomedical research. Thus, with 
that in mind there was a need to discover additional molecular biomarkers that could 
correlate with clinical outcomes and treatment response. ER, PR biomarkers are currently 
used to predict response to endocrine therapy and HER2 to predict the benefit of 
trastuzumab treatment [64]. 
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ER stimulates BrCa cell growth by binding to regulatory elements in the genome. Thus, 
when ER is activated in BrCa patients they can benefit from anti-estrogenic therapy [64] 
and currently, ER detection is used to identify patients for adjuvant treatments targeting ER 
and its downstream targets, preventing BrCa proliferation [64]. PR is used as a biomarker 
alongside with ER. Indeed, it was shown that ER could stimulate PR expression and that 
PR in the presence of progesterone could modify the location at which ER binds to 
chromatin. Thus, this alteration could lead to a switch in the regulation of genes that take 
part in cell proliferation, apoptosis and differentiation and so, when PR is present in ER+ 
BrCa patients the prognostic is better [64].  
The third most used predictive biological marker is HER2. Its measurement is required on 
cases of invasive BrCa. HER2, when overexpressed, can activate MAPK and PI3K/AKT 
that leads to tumour growth, enhancing cell proliferation, invasion and metastization [20, 
64]. HER2 is overexpressed in 15-20% of BrCa cases and, when ER is overexpressed, in 
nearly 80% of BrCa cases [64, 65]. This biomarker is used for predicting response to anti-
HER2 therapy [64].  
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1.2 Hox genes and cancer 
 
1.2.1 Homeobox Genes and homeodomain 
 
HOX genes were primarily discovered in Drosophila and found to have a common sequence 
of 183bp, the homeobox, which encodes a 61-amino acid DNA-binding homeodomain 
(Fig.6) [66, 67]. This sequence was found to be expressed in all three kingdoms of 
multicellular organisms [66]. The conservation that is observed between all organisms, 
extends past the gene sequences into their relative positioning along the chromosome [68]. 
During vertebrate evolution, HOX genes underwent gene duplications followed by specific 
gene loss events, which resulted in 39 HOX genes divided in four clusters in mammals [69, 
70]. Holland and colleagues divided the HOX genes into several groups: group 1 and 2: 
(HOX1 and HOX2, set to be the “anterior” genes), group 3 (HOX3), group 4 (HOX4-8 genes, 
set to be the “central” genes), group 5 (HOX9-13 genes, set to be the “posterior genes” [71]. 
In humans, HOX clusters are located in four distinct chromosomal loci: HOXA Chr 7p15.3; 
HOXB Chr 17q21.3; HOXC Chr 12q13.3 and HOXD Chr 2q31, and each can contain 
between 9 to 11 genes [72, 73].  
These genes encode a family of transcription factors that regulate early morphogenesis, for 
example controlling the anterior-posterior and proximo-distal differentiation during 
development by interfering with the cell fate within these axes [68, 72, 74, 75]. In a certain 
way, HOX genes act as a selector gene, since their combinatorial expression can play a 
major role in identity of an individual body segment [76]. In addition, these genes were found 
to regulate cell proliferation, specification and cell death and are required for non-
transcriptional functions such as DNA replication and repair, and mRNA translation [77]. 
Interestingly, their position within the cluster reflects the relative positions of the structures 
that they specify along this axis. Thus, if a gene is at the 3’ end of a cluster it is expressed 
in anterior regions of the embryo, while if it is located closer to the 5’ it is expressed in more 
posterior regions of the embryo. Akam and colleagues, suggested that during early 
Drosophila development HOX expression domains are determined by three regulatory 
inputs: transcriptional regulation from earlier segmentation genes, cellular memory system 
based on the action of Polycomb/tithorax group proteins and cross-regulatory interactions 
among the HOX genes themselves [78].  
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Figure 6 - Localization of the Hox gene within the clusters and their expression in mouse embryos. 
In the left, a coloured box represents each Hox gene and the line represents the non-coding regions 
linking them [70]. Color‐coding highlights conserved relationships between Drosophila and 
mammalian Hox genes, and the paralogous relationships within the mammalian cluster. In the right, 
Hox expression along the antero-posterior and proximo-distal axes reflects the formation of distinct 
skeleton elements along these axes. 
 
1.2.2 Altered HOX gene expression in cancer 
 
As explained previously, these genes have a key role in development. However, they also 
are implicated in tumour initiation and progression during adulthood. In fact, atypical 
expression of homeobox genes have been described in tumours, and such can be due to 
re-expression of HOX genes that were only activated during embryonic development, and 
then gained expression in neoplastic cells [5, 79]. In some cases, there are homeobox 
genes that are expressed in neoplastic cells derived from tissues where that particular gene 
was not expressed in embryonic stages, or in other cases the homeobox genes can be 
downregulated in malignant cells that are derived from a tissue where a particular gene is 
expressed in the fully differentiated state [79]. The role of HOX genes in cancer seems to 
be highly tissue-specific, given that they can be up or downregulated, depending of the 
cancer tissue. For example, HOXA9 is silenced in lung cancer cases through epigenetic 
mechanisms but is upregulated in acute lymphocystic leukemia [80]. In contrast, HOXB13 
is upregulated in BrCa, but it is silenced in prostate cancer [80]. These genes can also have 
two distinct roles in tumours, acting as oncogenes by promoting cell growth and invasion, 
or as tumour suppressors by modifying cell survival and morphogenesis [81, 82].  
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Actually, HOX genes are often deregulated in both solid tumours and liquid tumours. This 
family of genes are expressed during hematopoiesis and each cluster have a specific 
pattern of lineage-restricted expression, where HOXA genes are expressed in myeloid cells, 
HOXB genes in erythroid cells, HOXC genes in lymphoid cells and HOXD genes are not 
expressed in this process. HOXA9 is one of the HOX genes that is widely studied, being a 
key regulator of hematopoiesis and as an oncogenic role in leukemia, enhancing the 
expression of proliferative genes and inhibiting apoptosis [83].  
HOX genes expression can be regulated through epigenetic control, as described for 
example for HOXA9 in lung cancer [80]. These genes have CpG islands in the promoters, 
and when silenced these islands can be found methylated. In addition, HOX gene 
expression can be affected by histone modifications [81]. In consequence of these 
mechanisms, among others, abnormal activity of HOX genes can affect pathways that 
promote tumourigenesis, or as a result of their altered expression they can maintain a more 
embryonic state through the activation of anti-apoptotic pathways or suppression of 
differentiation [81]. HOX genes can act as transcriptional activators in some types of cancer, 
but in other cases they have a role as transcriptional repressors, so upregulation and 
downregulation of these genes is crucial to promote tumourigenesis [84]. 
 
1.2.3 Altered HOX genes in breast cancer 
 
The mammary glands start to develop during embryonic development with the formation of 
the mammary line, or milk line, and differentiation of placodes within this line (Fig.7A). At 
birth, these placodes already descend into the underlying mesenchyme forming the 
rudimentary ductal structure of the mammary glands. Then, subsequent stages of 
development are observed during pubertal, pregnancy, lactation, and involution states. 
During puberty, branching morphogenesis initiates under the influence of growth hormone 
(GH), estrogen and insulin-like growth factor 1 (IGF1). Upon pregnancy, progesterone and 
prolactin combined action generates alveoli able to secrete milk during lactation. The 
involution state initiates when lactation stops and involves remodelling of the gland back to 
the pre-pregnancy state. These processes require a variety of signalling pathways that 
regulate specialized subpopulation of mammary stem cells potentiating drastic changes in 
the gland occurring with each pregnancy. Particular HOX genes have been implicated in all 
these development states of the mammary glands, participating in their embryonic 
development, branching morphogenesis, alveoli formation and involution processes [82, 85] 
(Fig.7B).  
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Several studies report abnormal HOX gene expression in BrCa: HOXA6, HOXA13, HOXB2, 
HOXB4, HOXB5, HOXB6, HOXB7, HOXB8, HOXB9, HOXC5, HOXC13, HOXD1, and 
HOXD8 [84]. Hur and colleagues quantified the expression levels of the HOX genes in BrCa 
using reverse transcriptase PCR showing that 14 out of 25 HOX genes, present statistically 
significant differences between malignant and non-malignant breast cancer tissues. Other 
studies regarding invasiveness and migration of BrCa cells, have demonstrated that 11 
HOX genes were up-regulated in BrCa in comparison with normal breast tissues [67]. 
However, there are HOX genes that are downregulated in BrCa. HOXA5, for example, 
presents decreased expression in 60% of BrCa, which has been associated to apoptosis 
modulation in BrCa [84]. Similarly, HOXD10 appears to have less expression in epithelial 
cells, as malignancy progresses. Indeed, when HOXD10 expression is restored in cell lines, 
cell migration seems to diminish [81]. 
 
Figure 7 - Hox gene expression and function during mammary gland (MG) development in mice (in 
article submitted [86]). A. MG embryonic development. Gene expression is colour-coded in the 
image. ep: epithelium; me: mammary ectoderm; mm: mammary mesenchyme. Note ventrolateral 
surface ectoderm (milk line) marked by the expression of HoxC8 at E.10.5 and then restriction of 
several Hox genes to mammary placodes or surrounding mesoderm in subsequent stages. B. MG 
development after birth and detected Hox gene expression. TEB: Terminal embryonic buds: AB: 
Alveolar buds; MA: mature milk alveoli. 
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1.2.4 HOXB7-9 genes in breast cancer 
 
HOXB7 has been associated with tissue development of the mammary gland and with BrCa 
development [85]. Microarray analyses suggest that HOXB7 is significantly overexpressed 
in both the primary cancer and distant metastasis [87, 88]. Moreover, in cell lines, 
overexpression of this gene is directly or indirectly responsible for regulating the expression 
of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), 
which promote BrCa progression [89]. Indeed, HOXB7 overexpression in BrCa has been 
associated to BrCa progression and to the promotion of the epithelial-to-mesenchymal 
transition (EMT), through up-regulation of bFGF and activation of the MAPK pathway [81, 
88, 90, 91]. Importantly, some studies suggest that HOXB7 overexpression increases 
resistance to tamoxifen through activation of receptor tyrosine kinase pathways.  
In other solid tumours, HOXB7 function has been associated to cancer progression and 
poor clinical outcome and suggested as a potential prognostic factor and therapeutic target 
[90]. Moreover, there are studies that reveal that this gene is overexpressed in nearly 60% 
of BrCa cases. This was seen either in cell lines (MDA-MB-231, MDA-MB-468, MDA-MB-
453, MCF-7, SkBr-3) or BrCa specimens [90, 91]. Interestingly, HOXB7 protein seems to 
have an important role in DNA repair. Rubin and colleagues have shown that BrCa cell lines 
expressing HOXB7 present an enhanced survival after irradiation, so this resistance could 
allow these cells to accumulate mutations that might lead to tumourigenesis [90].  
HOXB8, which is localized immediately after HOXB7, within the HOXB cluster, is known to 
be overexpressed in colorectal cancer (CRC), when compared to normal colon tissue [92]. 
A study performed by Wang and colleagues, revealed that when HOXB8 is silenced can 
lead to a decreased proliferation, migration and invasion of CRC cells [93]. In BrCa, HOXB8 
does not seem to be deregulated in cell lines or breast cancer tissues, taking in 
consideration gene expression detection performed using reverse transcriptase PCR [67].  
HOXB9, located after HOXB7 and HOXB8 in the cluster, and potentially sharing regulatory 
mechanisms with them, encode a transcription factor with major roles in mammary gland 
development [85]. Apparently, the deregulation of this gene is strongly associated to cancer 
progression, being involved in increment of cell migration, invasion, angiogenesis, and in 
the formation of lung metastasis derived from primary BrCa [94-96]. The relevance of its 
deregulation for cancer progression makes it an important prognostic factor in different 
cancer types [94, 95, 97]. 
HOXB9 expression and function, has been studied mainly in the gastric cancer (GC) 
context, where it has been associated with a poor survival rate, when overexpressed, 
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inducing tumour progression, invasion and occurrence of metastasis. Kato and colleagues 
revealed that HOXB9 expression increased in 51,7% of GC patients, and its expression 
was localized in the nucleus of the GC cells. Also, patients with “positive” HOXB9 
expression, seemed to exhibit a poorer prognosis when compared to those with a lower 
expression, being highly associated with lymphatic invasion and lymph node metastasis 
[98]. However, another study suggests that overexpression of HOXB9 in GC cells leads to 
an increase in the apoptotic rate, thus, reducing the metastatic ability [99]. In endometrial 
cancer, HOXB9 overexpression correlates with cell migration and to the upregulation of an 
oncogenic transcription factor (E2F3), which controls cell cycle, differentiation, apoptosis 
and response to stress [100]. The overexpression of HOXB9 was also linked to colon 
cancer, where it seems to contribute for the formation of metastasis and a poor survival rate 
of patients [101]. This transcription factor was studied in BrCa, being upregulated when 
compared to normal breast tissues and it was associated with lower overall survival, 
relapse-free survival, distant metastasis-free survival and post-progression survival for 
patients diagnosed with BrCa [102].  
Seki and colleagues studied HOXB9 expression in BrCa through immunohistochemical 
staining [103]. Regarding those results, it was notable that 69 (48,9%) of a total of 141 
tumour specimens stained positive and were associated with a higher nuclear grade [103]. 
Hayashida and colleagues, found HOXB9 to be overexpressed in 42% of all BrCa cases 
analyzed, especially on those with high histological grade. HOXB9 abnormal expression in 
BrCa was proposed to be a tumour progression factor rather than a tumour-initiating event, 
since its expression has oncogenic effects, such as inducing growth factors that can alter 
tumour-specific cell fates, angiogenic factors and also leading to the formation of metastasis 
[103, 104]. Indeed, HOXB9 levels of expression relate to an increased expression of VEGFs 
that contributes to tumour progression and influence intratumoural microvessel density 
(IMD), a measure of neovascularization surrounding the tumour tissue [105]. Thus, higher 
HOXB9 expression can increase IMD and, therefore, contribute to a worse prognostic in 
BrCa patients. Shrestha and colleagues also demonstrated that HOXB9 is upregulated in 
BrCa tissues, being its expression also higher in various tumour cells including ER+ BrCa 
cells, MCF7 [106]. Thus, HOXB9 overexpression in BrCa can be due to a higher estrogenic 
activity present in BrCa tissues [106].  
Other studies attempted to apply ionizing radiation to HOXB-overexpressing breast cells 
showing that they become more resistant due to an enhanced DNA damage response, due 
to an increase of baseline ataxia telangiectasia mutated (ATM) phosphorylation [107]. So, 
in non-irradiated cells HOXB9 can induce detectable DNA damage, such as double-strand 
DNA breaks, that will increase ATM phosphorylation, leading to DNA damage response. 
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Thus upon radiation, BrCa cells that are overexpressing HOXB9, have their ATM 
hyperactivated in the early stages of the double-stranded DNA break response, leading to 
a more rapid response. In fact, production of growth factors (GF) and cytokines can alter 
tumour microenvironment and modulates cell fate, resulting on an increase of tumour 
aggressiveness and chemotherapy resistance. Thus, HOXB9 overexpression triggers the 
production of TGF-β, which is GF, and it can alter cell fate by inducing EMT [107].   
In summary, HOXB9 overexpression can lead to an increased production of 1) TGF-β 
controlling cell cycle, inducing cell differentiation and promoting apoptosis; 2) ErbB ligands 
inducing epithelial to mesenchymal transition and invasion; 3) bFGF supporting 
differentiation 4) VEGFs, promoting angiogenesis; 5) NRG2 influencing growth, 
differentiation and survival of different cell types [104, 106]. Also, HOXB9 influences BrCa 
progression, triggering ErbB ligands and TGF-β production, which causes phosphorylation 
and posterior activation of HER2/3 and TGF-β pathways, respectively. Although, activation 
of HER2/3 promotes cell motility, the TGF-β pathway promotes EMT [107].  
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2. Preliminary Results 
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Our lab has been investigating the role of HOXB genes in BrCa, particularly HOXB7 and 
HOXB8. Primarily, the HOX expression profile was characterized through qPCR and 
western blot in MDA-MB-231 and MDA-MB-468 BrCa cell lines, followed by HOX functional 
analysis through knockdown of HOXB7 using specific siRNAs. These assays made us 
suggest that HOXB7 Tf may regulate CDH1. However, our lab then performed aggregation 
assays, after successfully knocking down HOXB7 in MDA-MB-231 cell line, using as control 
cells that form compact aggregation as spheroids (MCF-7). The results demonstrated that 
silencing of HOXB7 in MDA-MB-231 cells does not affect the rate of aggregate formation in 
the experimental condition, in comparison with the control. Thus, the silencing of HOXB7 
seems to be insufficient to modify the function of CDH1 proteins. 
In order to further explore the role of HOXB7 in BrCa, we went on to characterize its 
expression in distinct BrCa molecular subtypes, with the aim to update these analyses using 
the qPCR approach and also to facilitate the selection of the most suitable cellular models 
for future functional assays in vitro and in vivo. To this end, the lab expanded the analyses 
of gene/protein expression analyses to cell lines MCF-7, BT-474, SKBR3, MDA-MB-231 
and MDA-MB-468 (Fig.8A). Human tissues were also analyzed, belonging to a cohort of 
BrCa patients from IPO-Porto. The evaluation of the cell lines leads us to conclude that 
HOXB7 was overexpressed in all of them, in comparison with normal cells (MCF10A). 
However, the expression was particularly high in MCF-7 and BT-474, in accordance with 
previous studies by Hur and colleagues using RT-PCR instead of qPCR [67]. 
Complementary Western blot analyses further confirmed these results. Contradictory 
results emerged, however, when analyzing the expression levels of HOXB7 in the cohort of 
BrCa patients. Where, HOXB7 appeared to be more significantly expressed in normal 
breast (NBr) than in BrCa tissues. In addition, no significant differences were found in the 
expression levels of distinct BrCa molecular subtypes. Analyzing CDH1 expression in cell 
lines and tissues, we also noticed lack of differences between tissues belonging to distinct 
molecular subtypes, which were very clearly identified in the cell lines. Thus, these results 
suggested the need to increase the cohort of patients analyzed and to test methods of 
protein detection that might be more efficient to evaluate differential expression levels in 
NBr and BrCa tissues (immunohistochemistry).  
HOXB9 expression was also re-analyzed in our lab using qPCR and aiming to fulfill the 
same aims above described for HOXB7. The results showed that this gene is 
overexpressed in cell lines MCF-7, BT-474 and MDA-MB-231, when compared to MCF10A 
normal breast cells (Fig.8B). However, the expression levels of this gene were still 
uncharacterized in the cohort of BrCa patients from IPO-Porto previous to the initiation of 
this master thesis.  
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Figure 8 - HOXB7 (A) and HOXB9 (B) basal mRNA expression levels, analyzed by qPCR [108]. 
Expression levels of BrCa cells (MCF-7, BT-474, SKBR3, MDA-MB-231, MDA-MB-468) compared 
to normal breast cells (MCF10A). The * denotes p-value < 0,05, the ** denotes p-value < 0,01 by 
unpaired T test with Welch’s correction. 
 
Table 2 - BrCa cell lines that were used, represents different BrCa molecular subtypes. 
Breast cancer cell lines Molecular subtypes 
MCF10A Normal breast 
MCF-7 Luminal A 
BT-474 Luminal B 
SKBR3 HER2+ 
MDA-MB-231 Triple negative 
MDA-MB-468 Triple negative 
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3. Aims 
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Overall, this project aims to overcome limitations from the literature regarding the 
characterization of HOXB7 and HOXB9 expression, at a transcriptional and protein level 
and considering BrCa cell lines and patients’ biopsies from distinct molecular subtypes. This 
work will be important for the planning of future experiments aiming to further comprehend 
the function of these genes in BrCa.  
Our specific aims were: 
Aim 1 – Characterize basal expression profiles of HOXB9 in BrCa tissues from a cohort of 
patients from IPO-Porto (n=128) representatives of the distinct molecular subtypes, using 
qPCR and characterize protein expression profile of HOXB9 using cell lines representing 
all recognized molecular subtypes of BrCa by western blot;  
Aim 2 – Characterize HOXB7 and HOXB9 protein level in patients’ biopsies, through 
immunohistochemistry.  
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4. Material and Methods 
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4.1 Patients sample 
 
All human breast cancer and normal RNA samples were received from IPO-Porto. The BrCa 
samples were used to quantify HOXB9 protein and mRNA expression and HOXB7 protein 
expression. mRNA expression was analyzed through qPCR and protein expression through 
immunohistochemistry assay. This cohort group consisted of 127 patients, being 11 
patient’s cancer free and 117 patients with BrCa (table 8).  
 
Table 3 - Clinicopathological characteristics of the cohort group from IPO-Porto. 
Characteristic Values (%) 
Age (year), median (range) 60 (30-86) 
Primary tumour size (T) 
 
T1 13 (10,2%) 
T2 38 (29,7%) 
T3 55 (43,0%) 
Unknown 11 (8,6%) 
Recidive 33 (28,2%) 
Bone 10 (32,3%) 
Brain 2 (1,6%) 
Liver 3 (2,3%) 
Lung 2 (1,6%) 
Locoregional 2 (1,6%) 
Ganglionar 
Menungeal 
1 (0,8%) 
1 (0,8%) Ga glion r + Lung   ( , ) 
Bone + Lung 2 (1,6%) 
Lung + Liver 1 (0,8%) 
Locoregional + Bone 1 (0,8%) 
Ganglionar + Bone 1 (0,8%) 
Breast + Bone 
Pleural + Bone 
Bone + Lung + Brain 
Bone + Lung + Liver 
1 (0,8%) 
1 (0,8%) 
1 (0,8%) 
1 (0,8%) 
Histological Type 
 
Ductal invasive 99 (77,3%) 
Lobular invasive 7 (5,5%) 
Ductal invasive + DCIS 8 (6,3%) 
Unkwown 2 (1,6%) 
Metaplasic 
Normal Breast 
1 (0,8%) 
11 (8,6%) Molecular subtype 
 
Luminal A 33 (26,0%) 
Luminal B 42 (33,0%) 
Triple negative 32 (25,2%) 
HER2+ 
 
Normal Breast 
9 (7,1%) 
11 (8,6%) Normal 11 (8,7%) 
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4.2 cDNA synthesis 
 
Total RNA was subjected to reverse transcription for cDNA synthesis, using the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Vilnius, Lithuania) (Tab.2). 
To validate the cDNA synthesis, it was performed a PCR with GAPDH primers, adding 
reagents mix (New England Biolabs) to 0.5 μl of cDNA (Tab.3-4). A negative control was 
also used by adding 0.5 μl of RNase-free water instead of cDNA. The amplified products 
were then loaded into a 2% agarose gel, prepared by adding 1g of agarose in 50 mL of 1x 
TAE and dissolved in the microwave. The gel was cooled down and then 2 μl of Green Safe 
Premium were added (Nzytech, Lisboa, Portugal). The samples were prepared for the 
electrophoresis by adding 1 μl loading dye (Thermo Scientific, Lithuania, EU) to 5 μl of the 
amplified product. This mix was loaded into the agarose gel and run in 1x TAE buffer at 100 
V alongside a 1 kilobase (Kb) ladder (Solis Biodyne). PCR was performed in a DNA thermal 
cycler (Tgradient, Biometra, Germany) and PCR electrophoresed products were visualized 
using an ultraviolet spectroscopy (Molecular Imager ® Gel Doc™ XR+ Imaging System,  
Table 4 - cDNA synthesis. 
 
 
 
 
 
 
Table 5 - Components of the PCR reaction to validate cDNA synthesis. 
 
 
 
 
 
 
 
 
Reagents 
Reagents  
Volume (ul) 
(μl) RNA 10 
10x RT 
Buffer 
2 
25 x dNTP 
Mix 
0.8 
10x 
Random 
RT 
primers 
2 
Multiscribe 1 
Ribolock 0.5 
H2O 3.7 
Total 20 
Reagents  (μl) 
cDNA 0,5 
GAPDH F 0,5 
GAPDH R 0,5 
Master Mix 10 
H2O 8,5 
Total 20 
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Table 6 - PCR amplification protocol for GAPDH. Primer Forward: ACTGGCGTCTTCACCACCAT; 
Primer Reverse: TCTTGAGGCTGTTGTCATACTTC; Product size: 142 bp. 
 
4.2 Quantitative real-time PCR analysis 
 
Quantitative real-time PCR experiments (qPCR) were performed using glyceraldehyde-3-
phosphate dehydrogenate (GAPDH), as a reference gene. qPCR reactions for HOXB9 were 
done with 0.5μl of cDNA, 0.5μl of primer forward and reverse (Tab.5), 5μl of iTaq™ 
Universal SYBR ® Green SuperMix (Bio-rad, Hercules, CA, USA) and 3.5μl of 
DNase/RNase-free water. All experiments were carried in triplicates and were performed in 
real-time thermal cycler CFX96™ (Bio-rad, California, USA). 
Table 7 - HOXB9 and GAPDH primers sequence, product length and annealing temperature. 
Genes Primer Sequence (5’-3’) Product 
()(bp) 
(Bp)bp 
Annealing 
Temperature 
HOXB9 FW CTACGGTCCCTGGTGAGGTA 198bp 
60º RV TAATCAAAGACCCGGCTACG 
GAPDH FW ACTGGCGTCTTCACCACCAT 142bp 
RV TCTTGAGGCTGTTGTCATACTTC 
4.3 Immunohistochemistry  
 
Immunohistochemistry assays were performed using NovoLink Max Polymer Detection 
System, Leica, using antibodies against HOXB7 (n=71) and HOXB9 (n=76) proteins, which 
recurred protocol optimization. Primarily, slides were de-paraffinized with xylene and re-
hydrated in an ethanol series. Antigen retrieval was performed using sodium citrate and 
EDTA for HOXB7 and HOXB9 antibodies, respectively, in the microwave for 20 minutes in 
high power. Then, in order to neutralize endogenous peroxidase, peroxidase was used at 
0,6%, thus, the non-specific background staining becomes significantly decreased. 
Afterwards, the slides were washed in TBST. To block albumin and immunoglobulins, horse 
serum was used in 1:50 for 20 minutes. Subsequently, the slides were incubated with the 
primary antibody (Tab.6) overnight, approximately 18 hours. Following this first incubation, 
slides were incubated with post primary and polymer, which is used as a substitute for the 
secondary antibody, for 30 minutes each. Next, they were washed in TBST and PBS, 3 
minutes each. To develop peroxidase activity, DAB was used for 10 minutes. Hematoxylin 
was used, for 3 minutes, as a counterstain. Lastly, the slides were de-hydrated in an ethanol 
Conditions Step 1 Step 2 Step 3 Step 4 
Temperature 95ºC 94ºC 60ºC 72ºC 72ºC 4ºC 
Time 15 min 3 sec 90 sec 90 sec 10 min Forever 
Cycles 30   
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series and posteriorly were mounted. To assess the quality of the staining, positive controls 
have to be used. As positive control for the staining we used bladder carcinoma for HOXB7 
and colon adenocarcinoma for HOXB9. H-score was used for semiquantitive analysis of 
immunoreactivity of these antibodies. In summary, more than 2000 cells were counted in 
each sample, and the H-score was generated by adding the percentage of strongly stained 
nuclei, the percentage of moderately stained nuclei, and the percentage of weak stained 
nuclei, giving a possible range of 0-300 [109]. Receiver operating characteristic (ROC) 
curves analyzes were performed to select relevant thresholds for tumour positivity. The cut-
off score with both maximum sensitivity and specificity was selected in order to have the 
greatest number of cases correctly classified and to decrease the number of false positives 
[110].. In addition, overall survival curves were created by Kaplan-Meier estimates and 
compared by log-rank tests, and it was analyzed with percentile 50 [98].  
Table 8 - HOXB7 and HOXB9 Antibodies characteristics for immunohistochemistry assays. 
Protein Antibody  Species Type Incubation 
(hours) 
Dilution 
HOXB7 Sigma 
(HPA049940) 
Rabbit Polyclonal 18h 1:100 
HOXB9 Santa Cruz 
Biotechnology 
(sc-398500) 
Mouse Monoclonal 18h 1:150 
 
4.4 Western-Blot 
 
The purified proteins (25 ug) were loaded into the wells of a 12% SDS-PAGE gel, along 
with molecular weight marker (Color Prestained Standard Broad Range, New England 
Biolabs). The proteins were then transferred from the gel to a nitrocellulose membrane 
(Invitrogen by Thermo Fisher Scientific) and afterwards blocked with 5% non-fat milk in 
TBS-T for 1 hour and 30 minutes at room temperature (RT) under agitation. Blots of the 
protein extract were probed with β-tubulin antibody (Santa Cruz Biotechnology), laminin 
antibody (Invitrogen) and HOXB9 antibody (Santa Cruz Biotechnology) primary antibodies 
and incubated overnight at 4ºC under agitation. The blots were washed with TBS-T, and 
TBS and incubated with secondary antibodies at RT for 1 hour and 30 minutes. The 
secondary antibody used was ECL anti-mouse IgG (GE Healthcare). The blots were 
washed in TBS-T and TBS. Revelation was performed using the Clarity™ Western ECL 
Blotting Substrate chemiluminescent reagent (Bio-Rad) and the Chemidoc Imaging System 
(Bio-Rad).  
Table 9 - Antibodies characteristics for western blot. 
Protein  Primary Ab Dilution Secondary Ab 
AbaaaaaaAAb
Antibody 
Dilution Protein kDa 
kDakDawei
ght (kDa) 
HOXB9 Santa Cruz 
(sc-398500) 
1:200 Mouse 1:1000 32 
Β-tubulin Santa Cruz  
(5-1-2) 
1:200000 Mouse 1:1000 55 
Laminin Invitrogen 1:250 Mouse 1:1000 66 
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5. Results 
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5.1 HOXB9 in BrCa 
 
HOXB9 has been studied in different types of cancer, being associated with poorer 
prognosis in colon and gastric cancer. In addition HOXB9 deregulation in cancer appears 
associated to higher migration and invasiveness in oral squamous cell carcinoma [94, 98]. 
The limited number of studies regarding the function of HOXB9 in BrCa suggests an 
involvement in tumour growth and angiogenesis, being frequently associated with a worse 
prognosis [104, 106]. Its expression levels have been characterized in the past using RT-
PCR, which revealed that HOXB9 was overexpressed in BT474, MDA-MB-231 BrCa cell 
lines [67, 106]. In addition, the protein levels were analyzed, and 48,9% of the BrCa 
specimens stained positive for HOXB9 [103, 106]. 
After analyzing HOXB9 expression by qPCR in BrCa cell lines belonging to all clinically 
relevant molecular subtypes (in Preliminary Results), we used the same method to HOXB9 
expression in human tissues from a cohort of patients (n=127), belonging to distinct 
molecular subtypes and compare it with NBr (Tab.8; Fig.9,10).  
The median age at diagnosis of the cohort group was 60 years (range 30-86 years) and the 
majority of the tumours were pathologically diagnosed as ductal invasive (77,3%) (Tab.8). 
However some samples belong to other histological types such as lobular invasive (5,5%) 
and ductal invasive with ductal carcinoma in situ (DCIS) (6,3%), which was the second most 
common. This cohort group represents four distinct molecular subtypes: luminal A (n=33), 
luminal B (n=42), triple negative (n=32) and HER2+ (n=9). In addition, the metastasis 
occurrence was accountable for 33% of the patients, being the most common in bone 
(32,3%) followed by liver (2,3%).  
HOXB9 had slightly lower expression in BrCa tissue than NBr, however, statistical 
significance was not reached (p ˃ 0,076) (Fig.9A). Furthermore, when we look at the 
molecular subtypes separately, it seems that triple negative and HER2+ have lower HOXB9 
mRNA expression, in comparison with other molecular subtypes, although statistical 
significance was not reached (Fig.9B). Previous studies addressing HOXB expression in 
BrCa suggested us that not all, but just a particular sub-set of patients may present aberrant 
HOXB9 expression. In fact, analyses of HOXB7 in BrCa tissues fail to detect over-
expression in 100% of the cases, but instead showed higher expression in a percentage of 
60% of the breast tumours analyzed [91]. Therefore, we depicted a sub-set of patients from 
our cohort (n=28), based on the median value of expression level of NBr and found 
significant differences (p value < 0,05) with the NBr (Fig.9C). Analyzes considering the 
molecular subtypes within this subset of patients, suggest significant overexpression (p 
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value < 0,001) of HOXB9 in all types, with the exception of HER2+, which had only one 
case with increased HOXB9 expression (Fig. 9D).  
 
Figure 9 - Box-plots of mRNA expression levels of HOXB9 in normal (NBr=11) and breast cancer 
tissues (BrCan=117) analyzed by qPCR. Y-axis as the 2-∆CT values of HOXB9 expression. Outliers 
were identified by the SPSS software and indicated with ˚  when considered as “Mild Values” and with 
* when considered as “Extreme Values”. A. Comparison between NBr and BrCa tissues reveals no 
significant differences. B. Comparison between distinct molecular subtypes reveals that BrCa Triple 
negative and HER2+ seem to have lower expression than NBr tissue. Luminal A (n=33), Luminal B 
(n=43), Triple negative (n=32) and HER2+ (n=9). C. A group of 28 patients shown higher (p < 0,001) 
HOXB9 expression in comparison with NBr (n=11). D. That group was analysed considering their 
molecular subtype. Luminal A (n=9), Luminal B (n=13), Triple negative (n=6) and HER2+ (n=1). 
 
Thus, our results suggest that, or we have a considerably small percentage of cases in 
which HOXB9 is aberrantly expressed or the normal controls do not allow us to detect the 
real differential expression between normal and BrCa tissues. Indeed, when we plot 
together HOXB9 expression from normal breast cell lines (PCS-600-010, MCF10A) and our 
data from tissues, we detect much lower levels of expression in the cell lines than in NBr 
(Fig.10). Through, Mann-Whitney analysis with Bonferroni correction, BrCa tissue samples 
presents significantly differences in expression levels in comparison with both cell lines (p 
value < 0,05).  
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Figure 10 - Box-plots of mRNA expression levels of HOXB9 in human NBr and BrCa tissues in 
comparison with normal breast cells (PCS-600-010, MCF10A). HOXB9 is significant upregulated in 
NBr, when compared to the cell lines. Outliers were identified by the SPSS software and indicated 
with ˚ when considered as “Mild Values” and with * when considered as “Extreme Values”. Y-axis as 
the 2-∆CT values of HOXB9 expression. 
 
Furthermore, we have analyzed the differences of HOXB9 expression regarding the grade 
of the tumour. Thus, as we can observe through Kruskal-Wallis analysis, there were not any 
significant differences (p values ˃ 0,05) between the differents grades of the tumour (Fig. 
11). 
 
Figure 11 - Box-plots of mRNA expression levels of HOXB9 in the different tumour grades. Outliers 
were identified by the SPSS software and indicated with ˚  when considered as “Mild Values” and with 
* when considered as “Extreme Values”. Y-axis as the 2-∆CT values of HOXB9 expression. 
 
5.2 Basal protein profile of HOXB9 in BrCa cell lines 
 
In order to contribute to ongoing work in the lab aiming to characterize HOXB9 expression 
in cellular models’ representatives of the distinct BrCa molecular subtypes, I participated in 
the optimization of the western blot protocol for HOXB9 antibody. In terms of mRNA levels, 
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our team detected higher HOXB9 expression in MCF-7, BT474 and MDA-MB-231 cell lines 
when compared to MCF10A normal cells (in Preliminary Data). Here, we first conduct the 
protocol in one of these cell lines with higher expression levels of HOXB9 (MDA-MB-231), 
considering cytoplasm and nucleus extracts. Our results revealed higher levels of 
expression of HOXB9 in the nucleus than in the cytoplasm (Fig.12). Other replicates will 
now be conducted and densitometry analyses.  
 
 
 
 
 
 
 
 
 
 
 
5.3 HOXB9 protein expression  
 
In order to further explore the expression of HOXB9 in our cohort of patients, we also 
characterized the protein levels through immunohistochemistry (n=76) (Fig.13). NBr tissue 
(Fig. 13B), presents strong staining for HOXB9, meaning that a high percentage of those 
cells shows positivity for HOXB9. In contrast, we can observe that there are some BrCa 
tissues that do not show any positivity for HOXB9 (Fig. 13C). Moreover, HOXB9 was 
strongly stained in some BrCa tissues (Fig. 13D), additionaly staining was observed in the 
nucleus of BrCa cells (Fig. 13E), as mentioned in previous reports [98, 103]. Analyzing the 
number of cells with nuclear positivity with different stainings, allowed to calculate an H-
score value used to compare levels of expression in NBr and BrCa tissues These 
quantitative evaluations further suggest that NBr seems to have a higher expression of 
HOXB9 in NBr (n=9) than in BrCa (Fig.14A). In addition, a ROC curve analysis was 
performed in order to understand the better threshold between NBr and BrCa (Fig.14B). 
Therefore, a threshold with high percentage of sensibility and specifity would be the cut-off 
score leading to greatest number of cases which were correctly classified as having or not 
the clinical outcome, in our case the threshold set was 142,3, with AUC of 0,902, meaning 
that cases with a H-score of 142,3 were considered as NBr. Thus, BrCa cases with a H-
HOXB9 
Laminin 
Tubulin 
Figure 12 - HOXB9 basal protein expression level in MDA-MB-231 cell line by 
western blotting. 
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score above that cut-off, were considered to be overexpressed. Overall survival (Fig. 15) 
was also analyzed with percentile 50, where patients above that percentile were considered 
HOXB9 positive, however there were not any significant statistical differences between 
HOXB9 positive and negative patients, however it seems that HOXB9-positive patients 
have a slightly lower survival. Our results contradict previous studies reporting that HOXB9 
is overexpressed in 49% of breast tumours  analyzed [103]. 
In addition, we also analyzed the protein expression of HOXB9 in different molecular 
subtypes of BrCa and we did not observe any significant differences between them (p value 
˃ 0,05) (Fig. 16), the same results were obtained when we analyzed tumour grade (Fig. 17). 
 
 
 
Figure 13 - HOXB9 expression in different tissues by immunohistochemistry. (A) HOXB9 expression 
in colon cancer (positive control), magnification of 10x; (B) HOXB9 stained positive in NBr, 
magnification of 10x; (C) HOXB9 stained negative in BrCa tissue, magnification of 10x; (D) HOXB9 
stained positive in BrCa tissue, magnification of 10x; (E) Closer magnification (40x) of (D), HOXB9 
stains positive in the nucleus of breast cancer cells. 
A B 
C D 
E 
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Figure 14 - HOXB9 protein expression in BrCa tissue. (A) Box-plots of HOXB9 H-score in human 
NBr and BrCa tissues analyzed through immunohistochemistry. (B) ROC curve for HOXB9 and 
differences between NBr and BrCa. 
 
Figure 15 - Kaplan-Meier plots of overall survival in HOXB9-positive and HOXB9-negative patients 
with Breast Cancer. 
 
A B 
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Figure 16 - Box-plots of hoxb9 H-score in different molecular subtypes of BrCa. Through Kruskal-
Wallis analysis, we can observe that there are not any significant differences (p value ˃  0,05) between 
BrCa molecular subtypes. 
 
 
Figure 17 - Box-plots of HOXB9 H-score in different tumour grades. Through Kruskal-Wallis analysis, 
we can observe that there are not any significant differences (p value ˃ 0,05) between different 
tumour grades. 
 
5.4 HOXB7 protein expression 
 
In order to complete the analyses previously done in the lab aiming to characterize the 
expression of HOXB7 in a cohort of BrCa patients from IPO (in Preliminary Results), we 
made use of the expertise gained while analyzing HOXB9 expression in the course of this 
work and also performed immunohistochemistry analyses for HOXB7 proteins (NBr= 6; 
BrCa= 64) (Fig.18). Thus, we can observe that HOXB7 marked positively for our positive 
control (Fig. 18A), bladder cancer, as well for NBr tissue (Fig. 18B). However, there were 
cases where HOXB7 stained negatively (Fig.18C). However, we can observe that are cases 
of BrCa that stained positively for HOXB7 (Fig. 18D), and in a closer magnification we can 
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observe that HOXB7 stains positive in the nucleus of BrCa cells (Fig. 18E). As for HOXB7, 
quantitative analyses of protein expression suggest higher levels of expression in NBr than 
in BrCa (Fig.19). However, the limited number of NBr samples cannot be neglected. 
Regarding the threshold to distinguish NBr from BrCa tissues, we analyzed a ROC curve 
(Fig.19B), and the cut-off score was 284,4 with an AUC 0,989. In addition, through Kaplan-
Meier survival analysis, with the use of percentile 50, we determine that patients that were 
above that percentile, were considered as HOXB7 positive. Thus, we could verify that 
patients that were classified as HOXB7 negative, presented slightly lower overall survival in 
comparison HOXB7 positive patients, however statistical significance was not reached 
(Fig.20). As for HOXB7, our results contradict previous studies reporting that HOXB7 is 
overexpressed in 60% of BrCa cases analyzed [91]. In addition, we analyzed the protein 
expression of HOXB7 in different molecular subtypes through Kruskal-Wallis analysis, and 
as we can observe there are not any significant differences between them (p value ˃ 0,05) 
(Fig. 21). 
 
 
Figure 18 - HOXB7 expression in different tissues by immunohistochemistry. (A) HOXB7 expression 
in bladder cancer (positive control), magnification of 10x; (B) HOXB7 stained positive in NBr, 
magnification of 10x; (C) HOXB7 stained negative in BrCa, magnification of 10x; (D) HOXB7 stained 
positive in BrCa, magnification of 10x; (E) Closer magnification (40x) of (D), HOXB7 shows positive 
nuclear staining in breast cancer cells. 
 
A B 
C D 
E 
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Figure 19 - HOXB7 protein expression in BrCa tissue. (A) Box-plots of HOXB9 H-score in human 
NBr and BrCa tissues analyzed through immunohistochemistry. (B) ROC curve for HOXB7 and 
differences between NBr and BrCa. 
 
 
Figure 20 - Kaplan-Meier plots of overall survival in HOXB7-positive and HOXB7-negative patients 
with Breast Cancer. 
 
A B 
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Figure 21 - Box-plots of HOXB9 protein expression in different molecular subtypes of BrCa. Through 
Kurskal-Wallis analysis, we can observe that there are not any significant differences (p value ˃ 0,05) 
between BrCa molecular subtypes Outliers were identified by the SPSS software and indicated with 
˚ when considered as “Mild Values” and with * when considered as “Extreme Values”. 
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6. Discussion 
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6.1 HOXB genes and BrCa 
 
BrCa is the leading cause of death due to cancer among women, being the second most 
common cancer type that affects females [2, 103]. The role of HOX genes in embryogenesis 
has been focus of considerable attention, however HOX genes may also play a fundamental 
part in adult tissue, being essential in the cell memory program or for the formation of post-
embryonic structures, such as the mammary glands [67, 106, 111]. These genes have been 
described to be frequently deregulated in several types of cancer [84], affecting proliferation, 
migration, invasion, differentiation and angiogenesis [81, 103]. Thus, the aberrant HOX 
gene expression can be critical for tumour progression [84]. 
The HOXB cluster have been studied in BrCa and was found to be deregulated in BrCa cell 
lines using RT-PCR analyses [67]. Moreover, deregulation of some of these transcription 
factors can lead to tumour progression through stimulation of epithelial-to-mesenchymal 
transition and angiogenesis [112]. Furthermore, it has been shown that HOXB cluster genes 
were upregulated in tamoxifen resistant MCF-7 cell line, conferring sensitivity to the cells 
when knockdown occurs [5]. In addition, many HOXB genes were found to be associated 
with BrCa progression through regulation of growth and angiogenic factors [91, 106]. 
Despite all the reports, the molecular mechanisms by which HOXB genes affect BrCa 
development remains unclear. 
 
6.2 Role of HOXB9 in BrCa tissue 
 
As previously mentioned (in preliminary results), our lab started studying the expression of 
HOXB9 in BrCa cell lines and the results achieved using qPCR were in accordance with the 
ones obtained in the past using RT-PCR [67]. However, our analyses allowed us to compare 
the expression levels in distinct molecular subtype cellular models. MDA-MB-231, 
representing the triple negative subtype, had the highest levels of HOXB9 mRNA 
expression. However, qPCR analyses of BrCa tissues performed during this thesis revealed 
a different HOXB9 expression profile. In contrast to the cell line results, triple negative 
subtype tissues did not appear to be overexpressing HOXB9, when compared with normal 
tissues. Furthermore, HER2+ had the lowest level of HOXB9 expression, considering a 
limited number of for this subtype (n=9).  
Thus, our results higlight the need to increase the cohort of patient tissues representing 
distinct molecular subtypes, in order to characterize the expression of HOXB9 in distinct 
BrCa contexts. In additon, differences observed between cell lines and BrCa tissues can be 
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due to the use of random NBr tissue, which can increase variability. In fact, these tissues 
were retracted from mamoplasty procedures, from patients that did not have BrCa, but have 
an increased genetic risk due to hereditary factors. Moreover, optimal NBr controlos should 
be retracted from adjacent tumour tissue to be examined together with its corresponding 
BrCa tissue, due to BrCa genetic heterogenity [106]. Also, we did not have any control of 
the place within the tumour that was sampled to biopsy. Thus, the exact location of the BrCa 
biopsy might be an important parameter to compare molecular characteristics given the 
intra-tumoural heterogenity. These results will be, however, important to conduct future 
analyses integrating more NBr tissues, collected from locations adjacent to the tumours or 
from health human with no obvious genetic predesposition to develop cancer. 
Furthermore, if we take only the HOXB9-overexpressing group into consideration, we have 
a significant difference between BrCa tissue and NBr tissue (p< 0,05). In addition, through 
statistical analysis we can observe that there are significant differences between all BrCa 
molecular subtypes (p< 0,01) in comparision with NBr. Through Kruskal-Wallis test with 
Bonferroni correction, we detected that Luminal B subtype was significant overexpressed 
in comparison with NBr tissue (p < 0,05). In addition, when we take a closer look in tumour 
tumour grading, we verify that  thaht variable did not present significant differences (p value 
˃ 0,05) (Fig. 11). Thus, these results suggest that HOXB9 overexpresion is not a common 
feature of all BrCa patients, but most likely be specific for a sub-set of patients. However, 
our results makes us question if the use of random NBr tissue could , in fact, increase show 
a higher number of HOXB9-overexpressing patients. Thus, a randomized group and a 
greater number of control samples seems to be mandatory to better characterize HOXB9 
in BrCa tissue.  
In addition, given that use of our cohort sample of NBr tissue could be increasing variability 
to our analysis, we have decided to compare the levels of expression of our controls with 
cell lines representative of normal breast (PCS-600-010, MCF10A). Through Kruskal-Wallis 
non-parametric analysis with Bonferroni correction, we found that HOXB9 levels were 
significantly increased in NBr tissues in comparison to both cell lines (p< 0,05). This, further 
suggest us that NBr tissue variability could be interfering with our overall results. 
 
6.3 HOXB9 Protein profile in BrCa biopsies 
 
HOXB9 protein expression has been previously reported to be overexpressed in different 
cancer types, such in GC (51%) and BrCa (49%) [98, 103]. Our results suggest, however, 
that HOXB9 more expressed in NBr than in Brca, taking in consideration evaluation of 
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mRNA and protein levels. However, our immunohistochemistry analyses clearly shows 
HOXB9 in the nucleus of BrCa cells, in accordance with Seki and colleagues [103]. 
However, the study that found 49% of HOXB9-overexpressing patients used distinct 
methods, given that they scored their results in accordance to the staining (none, weak or 
strong), not using our method of H-score [103]. Our results seem to be also contraditory to 
the ones presented by Shrestha and colleagues, where they compared cell densities in 
each BrCa case and compared them to its adjacent NBr tissue, indicating that HOXB9 was 
overexpressed in BrCa [106]. In this case they had a smaller number of samples than us 
and their control group was from adjacent tissue from the tumour. This distinct results 
highlight the need to use appropriated controls to properly charcaterize HOXB9 expression 
in distinct moelcular BrCa subtypes. Furthermore, we did not observe any significant 
difference (p value ˃ 0,05) in HOXB9 protein expression between different molecular 
subtypes or tumour size (Fig. 16 and 17). Additionally, Kaplan-Meier curves for overall 
survival shows no signficant difference in our cohort group. However HOXB9 positive 
patients seemed to have a slightly lower survival, which is in accordance with another report 
[103]. Thus, this main differences between our results and others presented in previous 
reports could be due to variations in immunohistochemistry evaluation methods but most 
likely are due to the limited sample number. BrCa is a highly heterogeneous disease, so it 
is important to increase the number of tumour tissue samples and to acquire more NBr 
tissues, in order to reduce variability and charcaterize HOXB9-overexpression in light of 
BrCa molecular subtypes.  
 
6.4 Basal protein profile of HOXB9 in BrCa cell lines 
 
Taking in consideration our preliminary results of HOXB9 expression levels on BrCa cell 
lines, we decided to start protocol optimization allowing western blot analyses of HOXB9 
levels in MDA-MB-231 cells, the cell line with highest mRNA expression level. With that in 
mind, both the protein from the cytoplasm and the nucleus were used seperadetely, as well 
as protein from the cytoplasm and the nucleus together. Since, HOXB9 is a transcription 
factor, we thought that protein would have an higher level of expression in the nucleus. As 
we can see from (Fig. 12), nucleus protein has slightly more HOXB9 expression than the 
rest of the samples. However, we still consider that this protocol could be further optimized 
and then used to characterize HOXB9 expression on the rest of BrCa cell lines trepresenting 
all recognized BrCa molecular subtypes. Thus, these results contributed to complete the 
carcaterization of HOXB9 expressionconsidering the distinct molecular subtypes, that will 
be advantage to explore their function in distinct oncological contexts in the future.  
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6.5 HOXB7 protein expression 
 
HOXB7 was reported to be overexpressed in BrCa tissues and cell lines [90, 91], which was 
in accordence to our preliminary results in vitro, wherein we demonstrate that MCF-7, BT-
474, MDA-MB-231 and MDA-MB-468 BrCa cell lines overexpresse HOXB7. Furthermore, 
it was also reported that HOXB7  was overexpressed in BrCa tissue samples of IDC [91], 
However our preliminary data demonstrated an opposite tendency, whereby HOXB7 was 
found to be significantly upregulated in NBr in comparion with BrCa [108]. The quantitative 
evaluation of the immunohistochemistry data, demonstrated that NBr has higher levels of 
HOXB7 protein than BrCa tissues. Thus, these results are in accordence with our 
preliminary results evaluating mRNA levels, which also show higher expression of HOXB7 
in NBr than BrCa tissues. Regarding, differences between all BrCa molecular subtypes, it 
was not visible any significant statistical variations (p value ˃ 0,05) among them (Fig. 
21).Thus, as mentioned while discussing reults for HOXB9, we believe that increment of 
NBr tissue samples could potentially diminuish variability in our study. In addition, given that 
BrCa is highly heterogenety disease, it would be important to increase sample number to 
better characterize HOXB7 expression patterns in BrCa tissues representing distinct 
molecular subtypes. In addition, Kaplan-Meier curves for overall survival were analyzed with 
percentile 50, and demonstrated that patients with lower HOXB7 expression had sligthly 
lower overall survival, however, statistical signifcance was not reached.  
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7. Conclusions 
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In this work, we attempted to provide the first quantitative analyses of HOXB9 
expression in normal and breast cancer tissues representing all major molecular 
subtypes using qPCR.  
In addition, we aimed to optimize immunohistochemistry protocols allowing HOXB7 and 
HOXB9 protein detection by immunohistochemistry in these samples, which we 
consider to be important to further characterize their degree of de-regulation in distinct 
BrCa molecular subtypes. We successful obtained positive staining of HOXB7 and 
HOXB9 in the nucleus of the cells, as reported in other studies using the same 
antibodies. Protein and mRNA quantitative analyses, however, provide results that 
contradict the literature and the data obtained by our lab using in cell lines: HOXB7 and 
HOXB9 seemed to be in higher levels in normal breast than in breast cancer tissues. 
The data collected will be valuable with the addition of more samples, both “normal” and 
from breast cancers from distinct molecular subtypes. Due to the heterogeneity of breast 
cancer, it would be optimal to obtain control tissues adjacent to the tumour to reduce 
the variability of the data. 
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